| 2018 | Marked Loss of Muscle, Visceral Fat, or Subcutaneous Fat After Gastrectomy Predicts Poor Survival in Advanced Gastric Cancer: Single-Center Study from the CLASSIC Trial | ANNALS OF SURGICAL ONCOLOGY |
| 2013 | Mechanism of enhancement of radiation-induced cytotoxicity by sorafenib in colorectal cancer
| JOURNAL OF RADIATION RESEARCH |
| 1998 | Menstrual state should be considered in determining sero-positivity of soluble angiogenic factors in breast cancer. | INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE |
| 2019 | Mesothelin Expression Is a Predictive Factor for Peritoneal Recurrence in Curatively Resected Stage III Gastric Cancer | ONCOLOGIST |
| 2018 | MET in gastric cancer with liver metastasis: The relationship between MET amplification and Met overexpression in primary stomach tumors and liver metastasis. | JOURNAL OF SURGICAL ONCOLOGY |
| 2013 | Metastatic non–clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria | CANCER |
| 2012 | Methylation status of lamin A/C in gastric cancer cell lines. | HEPATO-GASTROENTEROLOGY |
| 2011 | MMP-2 as a putative biomarker for carcinomatosis in gastric cancer | HEPATO-GASTROENTEROLOGY |
| 2008 | Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer | CANCER LETTERS |
| 1999 | Modulation of biological phenotypes for tumor growth and metastasis by target-specific biological inhibitors in gastric cancer | International Journal of Molecular Medicine |
| 2017 | Modulation of HAT activity by the BRCA2 N372H variation is a novel mechanism of paclitaxel resistance in breast cancer cell lines | BIOCHEMICAL PHARMACOLOGY |
| 2007 | Molecular basis of the differences between normal and tumor tissues of gastric cancer | BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE |
| 2010 | Molecular characterization of alternative SET-NUP214 fusion transcripts in a case of acute undifferentiated leukemia. | CANCER GENETICS AND CYTOGENETICS |
| 2023 | Monitoring the Outcomes of Systemic Chemotherapy Including Immune Checkpoint Inhibitor for HER2-Positive Metastatic Gastric Cancer by Liquid Biopsy
| YONSEI MEDICAL JOURNAL |
| 2001 | Monthly 5-days 5-fluorouracil and low-dose leucovorin for adjuvant chemotherapy in colon cancer | CANCER LETTERS |
| 2007 | Multi-institutional phase II study of S-1 monotherapy in advanced gastric cancer with pharmacokinetic and pharmacogenomic evaluations
| ONCOLOGIST |
| 2022 | Multicenter phase Ib/II study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: Updated HER-RAM study with biomarker analysis | JOURNAL OF CLINICAL ONCOLOGY |
| 2013 | Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide | INVESTIGATIONAL NEW DRUGS |
| 2008 | Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer | BREAST CANCER RESEARCH AND TREATMENT |
| 2018 | Multidisciplinary treatment for patients with stage IV gastric cancer: the role of conversion surgery following chemotherapy
| BMC CANCER |
| 2024 | Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study | LANCET ONCOLOGY |
| 2015 | Neoadjuvant chemoradiotherapy followed by D2 gastrectomy in locally advanced gastric cancer
| WORLD JOURNAL OF GASTROENTEROLOGY |
| 2005 | Neoadjuvant chemotherapy with infusional 5-fluorouracil, adriamycin and cyclophosphamide (iFAC) in locally advanced breast cancer: an early response predicts good prognosis
| ANNALS OF ONCOLOGY |
| 2007 | Novel and simple transformation algorithm for combining microarray data sets
| BMC BIOINFORMATICS |
| 2023 | Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
| SCIENTIFIC REPORTS |
| 2010 | Novel sunitinib strategy in metastatic renal cell carcinoma on hemodialysis: intermittent dose of sunitinib after hemodialysis.
| CANCER RESEARCH AND TREATMENT |
| 2017 | Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial | LANCET ONCOLOGY |
| 2009 | Oncogenic pathway combinations predict clinical prognosis in gastric cancer
| PLOS GENETICS |
| 2008 | OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation
| PLOS ONE |
| 2024 | Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study | JOURNAL OF CLINICAL ONCOLOGY |
| 2015 | Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium | CLINICAL GENITOURINARY CANCER |
| 2018 | Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma | BRITISH JOURNAL OF CANCER |
| 2023 | Outcomes of an Acute Palliative Care Unit at a Comprehensive Cancer Center in Korea
| PALLIATIVE MEDICINE REPORTS |
| 2010 | Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2014 | Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials
| ANNALS OF ONCOLOGY |
| 1996 | Overexpression of c-ErbB-2 Protein in Gastric Cancer by Immunohistochemical Stain | ONCOLOGY |
| 2012 | Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy
| PLOS ONE |
| 1997 | P-glycoprotein: The intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer | BREAST CANCER RESEARCH AND TREATMENT |
| 2016 | p16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with Metastatic Colorectal Cancer
| CANCER RESEARCH AND TREATMENT |
| 2021 | p16 methylation is a potential predictive marker for abemaciclib sensitivity in gastric cancer | BIOCHEMICAL PHARMACOLOGY |
| 1998 | p53 유전자 변형이 발생한 위암세포주에서 유전자이상 교정에 의한 항암제 감수성 변화
| Journal of the Korean Cancer Association (대한암학회지) |
| 2003 | Paclitaxel and Cisplatin Combination Chemotherapy in Pretreated Breast Cancer
| CANCER RESEARCH AND TREATMENT |
| 2015 | Pain palliation in patients with bone metastases using magnetic resonance-guided focused ultrasound with conformal bone system: a preliminary report.
| YONSEI MEDICAL JOURNAL |
| 2024 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer
| ESMO OPEN |
| 2012 | Patterns of regional recurrence after curative D2 resection for stage III (N3) gastric cancer: implications for postoperative radiotherapy | RADIOTHERAPY AND ONCOLOGY |
| 2023 | PBRM1-deficient PBAF complexes target aberrant genomic loci to activate the NF-κB pathway in clear cell renal cell carcinoma | NATURE CELL BIOLOGY |
| 2022 | PD-L1 expression and overall survival in Asian and western patients with gastric cancer | FUTURE ONCOLOGY |
| 2023 | Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial | LANCET ONCOLOGY |
| 2023 | Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial | LANCET |
| 2021 | Pemetrexed plus cisplatin in patients with previously treated advanced sarcoma: a multicenter, single-arm, phase II trial
| ESMO OPEN |
| 2013 | Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2013 | Pharmacogenomic Assessment of Outcomes of Pemetrexed-Treated Patients with Adenocarcinoma of the Lung
| YONSEI MEDICAL JOURNAL |
| 2021 | Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations
| INVESTIGATIONAL NEW DRUGS |
| 2023 | Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms
| FRONTIERS IN ONCOLOGY |
| 2009 | Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies. | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 1998 | Phase I clinical trial: pharmacokinetics of a novel anthracycline, DA-125 and metabolites. Single dose study | INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS |
| 2020 | Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma
| JOURNAL OF CLINICAL ONCOLOGY |
| 2008 | Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer | RADIOTHERAPY AND ONCOLOGY |
| 1994 | Phase Ib clinical trial and pharmacokinetic evaluation of recombinant human granulocyte-macrophage colony stimulating factor(rh GM-CSF LBD-005) in advanced cancer patients with chemotherapy induced myelosuppression
| Journal of the Korean Cancer Association(대한암학회지) |
| 2022 | Phase II Clinical Trial of Eribulin-Gemcitabine Combination Therapy in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma | CLINICAL CANCER RESEARCH |
